secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-06-26T20:07:59+00:00
Accession:  0001628280-26-045744
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics stockholders approve increase in authorized common shares to 300M
--------------------------------------------------------------------------------

- Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.
- All seven director nominees elected with >63M votes for each; no dissident candidates.
- Ratification of CohnReznick LLP as independent auditor for FY2026 approved with 72.76M votes.
- 91.88M shares outstanding; 79.27% quorum at annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/0001628280-26-045744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-045744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer